Cancer Control Journal Vol 3, No 2, CME Pretest

This Journal provides 4 hours of Category I Continuing Medical Education

Complimentary CME Credits

Physicans can earn up to 4 credit hours of Category I for the Physican's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions on the posttest at the end of this issue. Complete instructions are given on the posttest pages. Every successfully answered 10 questions will earn 1 credit hour. CME is presented by an unrestricted educational grant from Bristol-Myers Oncology Division.

Educational Objectives

After reading this issue, clinicians will be expected to:

• Know the limitations and benefits of screening for ovarian and large bowel cancer
• Be aware of the roles of cytoreductive surgery in ovarian cancer
• Understand the effects of hormone therapy in breast and gynecologic cancer patients
• Recognize the psychosexual impact of gynecologic cancer and its management
• Be familiar with the newer names of indolent lymphomas

Pretest

1. Results from NSABP B-14 study, in which a tamoxifen dose of 20 mg daily was used, have concluded thast the estimated annual risk of developing an endometrial cancer during tamoxifen use is:

a. 1 in 250

b. 1 in 500

c. 1 in 1000

d. 1 in 5000

2. Barakat recommends that endometiral sampling for women with breast cancer, whether taking tamoxifen or not, should be performed:

a. annually in all patients with a uterus

b. biennially in those over age 55 years

c. once, to determine the baseline endometrial status

d. with abnormal vaginal bleeding or brown discharge

3. McGuire et al have compared the effectiveness of cisplatin plus cyclophosphamide and cisplatin plus paclitaxel in patients with stage IV ovarian cancer. What was the overall response rate in the cisplatin plus paclitaxel arm?

a. 77%

b. 98%

c. 65%

d. 43%